Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Semaglutide: Evidence Summary
Evidence summary for Semaglutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Semaglutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Weight loss | Tier A | 8 | STEP trials — robust Phase III RCT data, FDA-approved |
| Type 2 diabetes | Tier A | 12 | SUSTAIN trials — FDA-approved for T2D |
| Cardiovascular risk reduction | Tier A | 4 | SELECT trial — significant MACE reduction |
| NASH/liver fibrosis | Tier B | 3 | Phase II data showing liver fat reduction |